BRAF and non-small cell lung carcinoma: In the NSCLC cohort of a basket study, vemurafenib achieved the ORR of 42% and median PFS of 7.3 months (95% CI, 3.5–10.8) among BRAF V600E–positive pre-treated NSCLC patients (18).